*All compounds discussed in this article—including Melanotan II (MT-II)—are for laboratory research purposes only. They are not intended for human use, medical treatment, or any application outside of controlled scientific investigation. This content is strictly educational and does not constitute medical advice.*
Melanotan II research has expanded significantly since the peptide was first synthesized at the University of Arizona in the 1990s. Originally developed as a non-selective melanocortin receptor agonist to study pigmentation pathways, the melanotan 2 peptide has become one of the most investigated compounds in the cosmetic peptide landscape, with implications reaching beyond melanogenesis into metabolic regulation, sexual function, and photoprotection research.
This guide provides a thorough review of the published MT-II tanning peptide literature, examines receptor pharmacology, surveys dosage parameters used in preclinical models, and identifies current gaps in the evidence base. For a broader introduction to cosmetic and dermatological peptides, visit our Cosmetic Peptides Guide.
Understanding Melanotan II: Structure and Receptor Pharmacology
What Is Melanotan II?
Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH) with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂. The structural modifications—substitution of norleucine for methionine at position 4 and cyclization of the peptide backbone—confer resistance to enzymatic degradation, substantially increasing its half-life relative to endogenous α-MSH.
Unlike its predecessor Melanotan I (afamelanotide), which is a linear peptide with selective MC1R affinity, MT-II is a non-selective agonist at multiple melanocortin receptor subtypes, which accounts for its broader pharmacological profile in research settings.
Melanocortin Receptor Activity
The melanocortin receptor family comprises five known subtypes, and MT-II demonstrates agonist activity at all of them:
- MC1R — The primary receptor mediating pigmentation effects. MC1R activation stimulates melanogenesis and eumelanin production in melanocytes. This pathway is the target of melanotan II research focused on photoprotection and skin pigmentation.
- MC3R — Involved in energy homeostasis and metabolic regulation. MT-II’s activity at MC3R contributes to observed appetite suppression effects in preclinical models.
- MC4R — The primary receptor mediating appetite suppression and sexual function effects. MC4R agonism has been the focus of research into obesity and erectile dysfunction models.
- MC5R — Associated with sebaceous gland regulation and exocrine function; less characterized in the context of MT-II research.
This multi-receptor pharmacology means that MT-II produces a wider range of effects than selective MC1R agonists, a distinction that is critical for interpreting research data and designing controlled experiments.
Melanogenesis and Photoprotection Research
Mechanism of Melanin Production
In melanotan II dosage research, the pigmentation pathway has been the most extensively studied effect. When MT-II binds MC1R on melanocytes, it activates a signaling cascade involving:
- Adenylate cyclase activation — Increases intracellular cAMP
- MITF upregulation — Microphthalmia-associated transcription factor drives tyrosinase, TRP-1, and TRP-2 expression
- Eumelanin synthesis shift — Promotes production of dark brown/black eumelanin over reddish pheomelanin
- Melanosome maturation and transfer — Enhanced melanosome development and transport to surrounding keratinocytes
The net effect in cellular and animal models is increased melanin density in the epidermis without requiring UV radiation—a finding with significant implications for photoprotection research.
Preclinical Melanogenesis Data
Published melanotan 2 peptide studies have characterized the following melanogenic effects:
- In vitro: MT-II stimulates melanin production in cultured human melanocytes at nanomolar concentrations, with dose-dependent increases in tyrosinase activity measurable within 48–72 hours of exposure
- Animal models: Hairless and pigmented murine models demonstrate significant increases in epidermal melanin density following subcutaneous MT-II administration over 1–3 week periods
- Photoprotection: MT-II-treated animal models show reduced UV-induced DNA damage (measured by cyclobutane pyrimidine dimers) compared to untreated controls, consistent with increased eumelanin providing a UV-absorptive barrier
Melanotan II Dosage Research: Preclinical Parameters
In published preclinical investigations, melanotan II dosage research has employed a range of administration protocols:
- Murine melanogenesis models: Subcutaneous doses ranging from 0.01–1.0 mg/kg/day for 7–21 days, with dose-dependent increases in skin darkness observed
- Metabolic studies: Single and repeated doses of 0.1–0.5 mg/kg subcutaneously, evaluating appetite suppression and weight change endpoints
- Sexual function models: Acute doses of 0.025–0.1 mg/kg subcutaneously, with effects onset within 15–60 minutes
These parameters are presented for research context only and do not constitute dosing recommendations. All dosing should be determined through institutionally approved experimental protocols with appropriate concentration controls.
Metabolic and Appetite Suppression Effects
MC4R and Energy Homeostasis
Beyond pigmentation, MT-II has been extensively studied for its metabolic effects mediated primarily through MC4R:
- Appetite suppression: Multiple animal studies demonstrate significant reductions in food intake following MT-II administration, with effects observable within hours
- Weight reduction: Chronic MT-II dosing in diet-induced obesity models produces measurable weight loss, even when controlling for reduced caloric intake
- Lipolysis stimulation: MT-II increases lipolytic activity in adipose tissue explants, suggesting direct effects on fat metabolism beyond appetite suppression
- Insulin sensitivity: Some evidence suggests MT-II may improve insulin sensitivity through central MC4R-dependent pathways
Research Limitations
MT-II’s lack of receptor selectivity complicates metabolic research interpretations. Appetite suppression observed in MC4R-knockout models is attenuated but not abolished, suggesting that MC3R and possibly other receptor subtypes contribute to the anorectic effect. Researchers should consider these multi-target effects when designing metabolic studies with MT-II.
Melanotan II vs Melanotan I: Research Comparison
| Parameter | Melanotan II (MT-II) | Melanotan I (Afamelanotide) |
|—|—|—|
| Structure | Cyclic heptapeptide | Linear 13-amino acid peptide |
| Receptor selectivity | Non-selective MC1R–MC5R agonist | Selective MC1R agonist |
| Primary research use | Melanogenesis, metabolism, sexual function | Photoprotection, melanogenesis |
| Administration in research | Subcutaneous injection | Subcutaneous implant (16 mg depot) |
| Half-life (preclinical) | ~1–2 hours | Longer (depot formulation extends release) |
| Off-target effects | Significant (appetite, sexual function) | Minimal beyond pigmentation |
| Research maturity | Moderate | High (FDA-approved for EPP as Scenesse®) |
This comparison illustrates that while both peptides target melanocortin pathways, MT-II’s non-selective pharmacology produces a broader range of effects—advantageous for multi-system research but requiring careful controls when isolated MC1R effects are the primary endpoint.
Safety and Tolerability in Research Models
Observed Effects in Preclinical Studies
In controlled laboratory investigations, MT-II has been associated with several dose-dependent effects beyond the target melanogenic and metabolic endpoints:
- Transient nausea: The most commonly reported effect in studies, mediated by MC3R/MC4R activation in the brainstem
- Flushing: MC1R-mediated peripheral vasodilation produces skin flushing in research models
- Priapism risk: In male animal models, high doses can produce prolonged erections via MC4R spinal pathways—this effect has been documented as a dose-limiting finding in some studies
- Hyperpigmentation: Extended dosing produces significant darkening of pre-existing nevi and freckles, a consideration for dermatological study design
Research Handling and Stability
- Lyophilized storage: Stable at -20°C for extended periods; room temperature stability is adequate for short-term handling
- Reconstitution: Bacteriostatic water recommended; reconstituted solutions require refrigeration (2–8°C) and protection from light
- Stability post-reconstitution: 2–4 weeks refrigerated; freeze-thaw cycles should be avoided
For comprehensive cosmetic peptide handling guidance, see our Cosmetic Peptides Guide.
Frequently Asked Questions
What is melanotan II used for in research?
Melanotan II is studied primarily as a non-selective melanocortin receptor agonist. Its most common research applications include melanogenesis and photoprotection pathways (MC1R), appetite suppression and metabolic regulation (MC3R/MC4R), and sexual function pharmacology (MC4R). The melanotan 2 peptide serves as a valuable pharmacological tool for interrogating melanocortin signaling across multiple receptor subtypes.
How does melanotan II differ from melanotan I in research?
Melanotan II is a cyclic heptapeptide with non-selective agonist activity at melanocortin receptors MC1R through MC5R, producing effects on pigmentation, appetite, and sexual function. Melanotan I (afamelanotide) is a linear peptide with selective MC1R affinity, limiting its effects primarily to melanogenesis. MT-II is shorter-acting but more pleiotropic, while afamelanotide has a longer duration of action and a more targeted pharmacological profile.
What dosage parameters have been used in melanotan II research?
In published preclinical melanotan II dosage research, subcutaneous doses ranging from 0.01–1.0 mg/kg/day have been evaluated across murine models. Melanogenesis studies typically employ 2–3 week dosing periods, while metabolic and sexual function endpoints have been measured after both acute and chronic administration. These parameters are presented for research reference only and should be validated through pilot experiments.
Is melanotan II the same as the MT-II tanning peptide?
Yes. Melanotan II, MT-II, and “MT-II tanning peptide” all refer to the same synthetic cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂). The various names reflect different naming conventions in the literature; the scientific community uses “Melanotan II” or “MT-II” most commonly.
Can melanotan II be combined with other cosmetic peptides in research?
Co-administration of MT-II with other cosmetic peptides—such as GHK-Cu for skin repair models—is theoretically possible in multi-modal study designs. However, MT-II’s systemic melanocortin receptor activity and potential off-target effects require careful experimental controls. Researchers interested in skin remodeling may also find our GHK-Cu Hair Research guide relevant for designing combination protocols.
Where can I find more information on cosmetic peptide research?
Our Cosmetic Peptides Guide provides a comprehensive overview of the cosmetic peptide landscape including GHK-Cu, argireline, Matrixyl, and additional compounds relevant to dermatological and aesthetic research.
Related Guides
- Cosmetic Peptides Guide — Comprehensive overview of cosmetic and dermatological research peptides
- GHK-Cu Hair Research — Copper peptide effects on hair follicle biology and skin remodeling
Research Products
For qualified researchers and institutions, the following product is available for laboratory research:
- Melanotan II (MT-II) — Research-grade melanocortin receptor agonist for melanogenesis, metabolic, and pharmacological studies
Disclaimer: All products and compounds referenced on this page are intended exclusively for laboratory research purposes. They are not for human consumption, medical use, or any application outside of controlled scientific research. Statements made herein have not been evaluated by the FDA. This content is for educational and informational purposes only and does not constitute medical advice, clinical recommendation, or endorsement of any compound for therapeutic use.